Medicare will pay for screening for cognitive impairment but that doesnt mean its necessarily a good idea The US Preventive Services Task Force   in March that there isnt enough scientific evidence to make the call Thats the same conclusion that the task force an independent panel of medical experts came to more than a decade ago when it last evaluated dementia screening Patient advocates say the evidence is crystal clear in one respect More research needs to be done Its kind of a Catch says Dean Hartley director of science initiatives at the   The USPSTF believes there are tests that are of value but theres not enough evidence But we need to collect that evidence to suggest that this is something we should do on an annual basis Dementia screenings are typically short questionnaires that test memory attention language andor visuospatial skills among other things One of the most common the   consists of  questions and may be completed in about  minutes When the USPSTF evaluated the evidence related to screening tests it found that while some tests could accurately identify dementia there wasnt enough evidence to show that there was either benefit or harm in routine screening of people over  There wasnt enough evidence to show that screening decisively affected peoples treatment or decision making and planning among other things Under the Affordable Care Act Medicare beneficiaries are entitled to an   with no outofpocket charge In addition to routine checkup items like measuring weight and blood pressure the visit covers an   The Alzheimers Association recommends that seniors undergo cognitive impairment screening and evaluation with a trained medical professional to establish a baseline for comparison and then have regular followup assessments in subsequent years  is the sixth leading cause of death killing more than  people annually It accounts for up to  percent of all dementia cases Other types of dementia include vascular dementia many cases of Parkinsons disease and Huntingtons disease We recognize this is an important disease of high consequence and a problem that will only increase over time says   professor and chair of geriatrics and palliative care at Mount Sinai School of Medicine in New York who was covice chair of the task force on dementia screening We are hopeful that in coming years when we have to revise this recommendation well have better evidence on effectiveness of early diagnosis But were not there in 